Celladon’s Mydicar Fails In Phase IIb, But Don’t Count Out Gene Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Shares of uniQure, Spark Therapeutics and bluebird bio all opened lower April 27 after Celladon announced its heart failure gene therapy Mydicar failed to show a benefit versus placebo in a mid-stage trial.